Floatz Rating
D30/100
Confidence
Indicative
Sponsor
The First Affiliated Hospital of Soochow University
Modality
Small molecule
Development Phase
N/A
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
15Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07609446CT.gov Pomalidomide Plus Anti-CD20 Antibody and Prednisone in Frontline Indolent B-Cell Lymphoma | — | Not Yet Recruiting | — | — | — |
NCT07257510CT.gov Pomalidomide Plus Orelabrutinib and Zuberitamab in Untreated Mantle Cell Lymphoma | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Mantle Cell Lymphoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Pomalidomide (this asset) | The First Affiliated Hospital of Soochow University | N/A | D · 30 |
| Prednisone | National Cancer Institute (NCI) | P4 | BBB |
| Adriamycin | National Cancer Institute (NCI) | P4 | BBB |
| Etoposide | Ruijin Hospital | P4 | BB |
| Cyclophosphamide | Miltenyi Biomedicine GmbH | P4 | BB |
| Rituximab | City of Hope Medical Center | P4 | BB |
| (+)-Vincristine | National Cancer Institute (NCI) | P4 | BB |
| Cyclosporin A | Fred Hutchinson Cancer Center | P3 | BB |
| Vincristine Sulfate | M.D. Anderson Cancer Center | P2 | BB |
+42 more in the Mantle Cell Lymphoma cohort
Other indications for Pomalidomide
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Plasma Cell Myeloma | — | P4 | BB · 69 |
| Myelodysplastic Syndrome | — | P2 | B · 60 |
| Kidney Failure | — | P2 | B · 58 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Pomalidomide in Mantle Cell Lymphoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 14, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/pomalidomide-mantle-cell-lymphoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →